Biotechnology Diplomacy Leadership Act Proposes New Senior Official at State Department to Secure Global Competitive Edge

In a strategic move to centralize and elevate the United States’ approach to the rapidly evolving field of life sciences, Representative Rich McCormick (R-GA) formally introduced the Biotechnology Diplomacy Leadership Act, designated as H.R. 9755, on July 16, 2026. The legislation seeks to codify a new era of American foreign policy by establishing a dedicated, senior-level biotechnology lead within the U.S. Department of State. This official would be tasked with harmonizing the nation’s international biotechnology strategy, ensuring that the U.S. remains the preeminent global leader in an industry that is increasingly viewed as the primary engine of 21st-century economic growth and a critical frontier for national security.

According to a press release issued by Congressman McCormick’s office, the bill is a direct response to the escalating "global competition" in biotechnology. As nations race to master synthetic biology, genomic sequencing, and advanced pharmaceutical manufacturing, the United States faces unprecedented pressure from strategic rivals, most notably the People’s Republic of China, to maintain its technological edge. The bill’s introduction follows a series of urgent recommendations from the National Security Commission on Emerging Biotechnology (NSCEB), which warned that the current administrative structure at the State Department is ill-equipped to handle the complexities of modern "bio-diplomacy."

The Mandate of the Senior Biotechnology Official

The core of H.R. 9755 is the creation of a Senior Biotechnology Official who will report directly to high-level leadership within the State Department. This position is intended to serve as the "nerve center" for U.S. interests in the global bioeconomy. The legislation outlines five primary responsibilities for this new office:

First, the official will coordinate U.S. biotechnology diplomacy across the entire federal government. Currently, biotechnology policy is fragmented among various agencies, including the Department of Commerce, the Department of Defense, the Department of Agriculture, and the Department of Health and Human Services. By creating a central node at the State Department, the bill aims to eliminate bureaucratic silos and ensure a unified American voice on the world stage.

Second, the official will serve as the principal advisor to the Secretary of State on biotechnology policy. This ensures that biological innovations—and the security risks they may carry—are factored into broader foreign policy decisions, from trade negotiations to human rights advocacy.

Third, the legislation emphasizes the need to deepen cooperation with allies and partner nations. This includes the harmonization of regulatory standards, the sharing of research and development (R&D) data, and the creation of "bio-secure" corridors for international collaboration.

Fourth, the official will be tasked with strengthening biotechnology supply chains. The COVID-19 pandemic and subsequent global disruptions highlighted the vulnerability of pharmaceutical and biological supply lines. The new lead will work to reduce dependencies on adversarial nations and secure the flow of precursor chemicals, specialized equipment, and active pharmaceutical ingredients (APIs).

Finally, the official will represent American interests in international biotechnology forums. This includes the United Nations, the World Health Organization (WHO), and standard-setting bodies where international norms regarding gene editing, data privacy, and biological weapons conventions are debated and established.

A Chronology of U.S. Biotechnology Policy Evolution

The introduction of the Biotechnology Diplomacy Leadership Act is the culmination of nearly half a decade of heightening focus on the "bio-revolution." To understand the significance of H.R. 9755, one must look at the timeline of events that led to its conception.

In September 2022, the Biden administration issued Executive Order 14081, "Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy." This order laid the groundwork for a whole-of-government approach to the sector. However, while the 2022 order focused heavily on domestic manufacturing and R&D, it left a gap in how the U.S. would manage the diplomatic and geopolitical ramifications of these technologies.

Throughout 2023 and 2024, the National Security Commission on Emerging Biotechnology (NSCEB) conducted extensive hearings and research. Their findings, released in a series of reports, suggested that the United States was falling behind in "norm-setting"—the process of establishing international rules for how biotech should be used. The NSCEB specifically noted that while the State Department has officials for nuclear non-proliferation and climate change, it lacked a senior figure dedicated to the transformative power of biotechnology.

By 2025, legislative momentum grew with the passage of the BIOSECURE Act, which targeted specific adversarial biotechnology companies and sought to protect American genomic data. However, policymakers realized that a purely defensive or restrictive posture was insufficient. H.R. 9755 represents the transition to an offensive, proactive diplomatic strategy, moving beyond just blocking rivals to actively leading a global coalition of bio-innovators.

The Economic and Strategic Data Driving the Bill

The urgency behind McCormick’s bill is supported by staggering economic projections. According to data from the McKinsey Global Institute, the direct annual economic impact of the global bioeconomy could reach $4 trillion by 2030-2040. This encompasses everything from new healthcare therapies and drought-resistant crops to bio-based plastics and carbon-sequestering materials.

Furthermore, the "datafication" of biology has turned genetic information into a high-value asset. The global genomics market alone is expected to surpass $100 billion by 2028. The U.S. currently leads in biotechnology R&D, accounting for approximately 40% of global biopharmaceutical revenue. However, China’s "Made in China 2025" and subsequent 14th Five-Year Plan have prioritized biotechnology as a "strategic emerging industry," with state-backed investments totaling tens of billions of dollars.

The NSCEB’s warnings about a lack of coordination at the State Department are underscored by the sheer number of international treaties and organizations that now touch upon biotechnology. From the Nagoya Protocol on access and benefit-sharing of genetic resources to the Biological Weapons Convention (BWC), the diplomatic workload has increased exponentially. Without a dedicated official, the U.S. risks being outmaneuvered in forums that decide the future of intellectual property rights and ethical boundaries for technologies like CRISPR-Cas9.

Official Responses and Stakeholder Reactions

While H.R. 9755 is a Republican-led initiative, it is expected to garner significant bipartisan support, mirroring the consensus seen in previous "China competition" bills. Representative McCormick, a physician by trade, has framed the bill as a matter of both health security and economic sovereignty.

"Biotechnology is not just about medicine; it’s about who controls the building blocks of life," McCormick stated in his July 2026 announcement. "If the United States does not lead in setting the global standards for this technology, our adversaries will. We cannot afford to have a State Department that treats biotechnology as a secondary concern. We need a leader who wakes up every day thinking about how to win this race."

Industry groups, including the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA), have expressed cautious optimism. While these organizations generally support increased diplomatic engagement to protect intellectual property abroad, they have also emphasized the need for the new official to work closely with the private sector to ensure that regulations do not stifle innovation.

National security experts have been more vocal in their support. Analysts from the Center for a New American Security (CNAS) noted that a dedicated biotechnology lead could help bridge the gap between "science diplomacy" and "hard-power security." They argue that the State Department needs an official who understands the dual-use nature of biotechnology—the fact that a laboratory designed for vaccine research can, in some cases, be repurposed for biological agent development.

Broader Implications: The Future of Bio-Diplomacy

The establishment of a Senior Biotechnology Official would signal a fundamental shift in how the United States perceives its role in the world. It marks the formalization of "Bio-diplomacy" as a core pillar of the State Department’s mission, alongside traditional areas like energy diplomacy and arms control.

If H.R. 9755 becomes law, the immediate impact will likely be felt in the Indo-Pacific region. The new official would likely prioritize the creation of a "Bio-Five" or similar coalition, involving key partners like Japan, South Korea, Australia, and the United Kingdom. This coalition would aim to create a trusted ecosystem for biotechnology, ensuring that sensitive research and supply chains remain within a circle of democratic nations that adhere to high ethical and safety standards.

Furthermore, the bill addresses the growing concern over "biological data sovereignty." As nations increasingly implement laws governing how the genetic data of their citizens can be shared across borders, the U.S. needs a diplomatic lead to negotiate agreements that allow for the free flow of scientific data while protecting individual privacy and national security.

In the long term, the Biotechnology Diplomacy Leadership Act could serve as a blueprint for how the U.S. government organizes itself to face other emerging technologies, such as artificial intelligence and quantum computing. By creating a dedicated lead for a specific technological domain, the government acknowledges that 20th-century diplomatic structures are no longer sufficient for 21st-century challenges.

As H.R. 9755 moves to the House Foreign Affairs Committee, its progress will be closely watched by scientists, diplomats, and tech leaders worldwide. The bill represents a recognition that the laboratory and the diplomatic cable are now inextricably linked, and that the future of American leadership may very well be written in the code of life itself. The successful passage and implementation of this act would ensure that the United States does not just participate in the biological revolution, but actively shapes its global trajectory for decades to come.